646 lodi

2025-01-12 2025 European Cup 646 lodi News

646 lodi Steve Noviello's 2024 Holiday Gift GuideBuy Smarter: The Consumer Guide to Smart TVs

MADISON, Wis. (AP) — President-elect Donald Trump’s former Wisconsin attorney lashed out Thursday at the state’s Democratic attorney general for filing felony charges against him and two others related to the 2020 fake electors scheme, saying after their initial court appearance that he was the victim of “lawfare” that wreaked havoc on his life. Jim Troupis, a former Wisconsin judge who represented Trump in 2020, was the only one of the three defendants to appear in person at the hearing. Kenneth Chesebro, an attorney who advised Trump’s 2020 campaign, and Mike Roman, Trump’s director of Election Day operations in 2020, appeared by phone. All three are charged with 11 felony forgery counts. Each charge carries a maximum penalty of six years in prison and a $10,000 fine. A court commissioner set a preliminary hearing for all three for Jan. 28. They will enter their pleas at their arraignment, which is not yet scheduled. Troupis, in comments after the brief hearing, said Wisconsin Attorney General Josh Kaul has “doubled down on a vicious strategy to destroy our very faith in the system of justice by using the courts for his own personal political game.” “My family and I have endured nonstop vicious and unrelenting savage attacks on my reputation, on my livelihood,” Troupis said outside of the courtroom surrounded by supporters, including Republican former Gov. Scott McCallum. “My children have been interrogated. My long-held friendships and professional life have been destroyed.” Kaul said in a written statement in reaction to Troupis that decisions in cases are based on the facts and the law. “In this case, like all other cases, we will litigate the issues in dispute in a court of law,” Kaul said. Troupis defended the strategy of having the GOP electors meet, saying it was necessary in case a court ruled that Trump won Wisconsin. “We had thought that this would end,” Troupis said. “The country asked for it to end in November, but lawfare in all its despicable forms will not end in Wisconsin.” Troupis and the other two defendants were ordered not to have contact with the 10 electors or three others not identified by name in the criminal complaint. They did not object to those conditions and were allowed to leave without posting any money for bail. The state charges against the Trump attorneys and aide are the only ones in Wisconsin. None of the electors have been charged. The 10 Wisconsin electors, Chesebro and Troupis all settled a lawsuit that was brought against them in 2023. There are pending charges related to the fake electors scheme in state and federal courts in Arizona , Michigan , Nevada and Georgia. Federal prosecutors investigating Trump’s conduct related to the Jan. 6, 2021, U.S. Capitol riot said the fake electors scheme originated in Wisconsin. Electors are people appointed to represent voters in presidential elections. The winner of the popular vote in each state determines which party’s electors are sent to the Electoral College, which meets in December after a presidential election to certify the outcome. The Wisconsin complaint details how Troupis, Chesebro and Roman created a document that falsely said Trump had won the state’s 10 Electoral College votes and attempted to deliver it to then-Vice President Mike Pence for congressional certification. Prosecutors said in the complaint that most of the 10 electors told investigators they needed to sign the elector certificate indicating that Trump had won only to preserve his legal options if a court changed the outcome of the election in Wisconsin. Most of the electors also said that they did not consent to having their signatures presented as if Trump had won without such a court ruling, the complaint said. Troupis and Roman filed four motions to dismiss the charge before Thursday’s hearing. The court commissioner did not consider those. The fake elector efforts were central to a 2023 federal racketeering indictment filed against Trump alleging he tried to overturn the results of the 2020 election. Special counsel Jack Smith moved to abandon that case last month, acknowledging that Trump’s return to the White House in January will preclude attempts to federally prosecute him. Trump was also indicted in Georgia along with 18 others accused of participating in a sprawling scheme to illegally overturn the 2020 presidential election there. Trump is trying to get that case dismissed , arguing that state courts won’t have jurisdiction over him when he returns to the White House next month. Chesebro and Roman were among those indicted with Trump in Georgia. Roman has pleaded not guilty to racketeering and conspiracy charges there, as well as to nine felony charges in Arizona related to the fake electors scheme in that state. Chesebro pleaded guilty to one felony charge of conspiracy to commit filing false documents in a deal with Georgia prosecutors. He is trying to invalidate the plea after the judge in September tossed out the charge against Trump and others. Associated Press writer Todd Richmond contributed to this story.

Article content Santé Québec is contemplating, as a last resort, “a selective reduction of services” to the population in a four-phase plan to slash $1.5 billion in spending within the province’s beleaguered health network, The Gazette can reveal. “They’re starting to talk about whether or not that’s somewhere where they need to go,” a high-ranking source said on Friday. “Nobody has decided that yet. They’ve got a four-phase plan for reducing spending. The fourth phase is a selective reduction of services. The other phases are mostly administrative, things like getting rid of unfilled positions, reducing your printing if you don’t need to print or getting rid of paper.” Asked what services might be cut, the source — who agreed to be interviewed on condition of anonymity because of the sensitivity of the issue — replied: “I haven’t heard any talk yet. We’re looking at it internally in our own organization and we’re scratching our heads.” However, the fact that Santé Québec is even mulling the possibility of cutting health services to the public underscores the gravity of the financial crisis. “Up until now, they were saying, ‘You can’t do anything to reduce service or access.’ But they’re now getting to the point where they’re actively considering what, if anything, that could be done to affect certain services. No decisions have been taken.” In a statement posted to the Bluesky social media platform (and emailed to The Gazette on Friday afternoon), Santé Québec confirmed a report last week by the newspaper that it has ordered hospitals and other facilities to chop nearly $1.5 billion from their budgets in the coming months — an amount that would be 50 per cent greater than previously known. “The accumulated deficit at mid-year (was) $1 billion,” Santé Québec noted in the statement. “Looking ahead to the end of the fiscal year in March 2025, the projected deficit could rise to as much as $1.5 billion if nothing is done. “There are three main reasons for the budget overrun,” the Crown corporation explained. “First, there has been an increase in demand for existing services, for example, mental health, home care and emergency room visits. Second, the development of new services to meet the needs of an aging population. Third, inflation, which was high at the beginning of the year.” On Friday evening, Catherine Domingue, a Santé Québec spokesperson, declined to confirm or deny the prospect of “a selection reduction of services,” referring a reporter instead to the earlier Bluesky post. Health Minister Christian Dubé created Santé Québec with a view to running the province’s $60-billion-a-year public health system more efficiently. “In anticipation of our taking office on Dec. 1, Santé Québec teams have been working with each of our facilities over the past few weeks to implement solutions, based on local realities, to generate greater efficiency and return to a balanced budget for the current year.” In its Bluesky post, Santé Québec emphasized the importance of “being transparent in communicating the state of finances in the health and social services network.” However, as soon as The Gazette published its story online last week citing the $1.5 billion figure, an official called a reporter to deny that sum. Santé Québec, headed by Geneviève Biron, had also considered the cost-cutting option of barring employees from holding down jobs at two hospitals. But after a public backlash, the organization announced it would give workers an extra year to adjust. Another austerity measure already in place is a hiring freeze on managers. The austerity measures are being driven by worries in the Legault government that U.S. bond-rating agencies might lower Quebec’s credit rating, which in turn could drive up the interest on debt payments by the provincial government. Quebec’s spending on health and social services has climbed to $60 billion in 2024-25 from about $35 billion six years ago, while the government has posted a record deficit of $11 billion this year. Even in the absence of direct cuts to services, health-care managers have expressed concern that any dramatic reduction in spending would inevitably result in problem with access, including longer wait times for surgery. “At some point there are going to be consequences. I mean, it’s not a matter necessarily of cutting service, but this could result in longer wait times,” a senior administrator had said in an interview. aderfel@postmedia.com x.com/aaron_derfel

No. 3 Nittany Lions relying on defensive depth in Big Ten title game and postseason runLil Wayne, GloRilla, Camila Cabello to perform at College Football National Championship

“Gladiator II” asks the question: Are you not moderately entertained for roughly 60% of this sequel? Truly, this is a movie dependent on managed expectations and a forgiving attitude toward its tendency to overserve. More of a thrash-and-burn schlock epic than the comparatively restrained 2000 “Gladiator,” also directed by Ridley Scott, the new one recycles a fair bit of the old one’s narrative cries for freedom while tossing in some digital sharks for the flooded Colosseum and a bout of deadly sea-battle theatrics. They really did flood the Colosseum in those days, though no historical evidence suggests shark deployment, real or digital. On the other hand (checks notes), “Gladiator II” is fiction. Screenwriter David Scarpa picks things up 16 years after “Gladiator,” which gave us the noble death of the noble warrior Maximus, shortly after slaying the ignoble emperor and returning Rome to the control of the Senate. Our new hero, Lucius (Paul Mescal), has fled Rome for Numidia, on the North African coast. The time is 200 A.D., and for the corrupt, party-time twins running the empire (Joseph Quinn and Fred Hechinger), that means invasion time. Pedro Pascal takes the role of Acacius, the deeply conflicted general, sick of war and tired of taking orders from a pair of depraved ferrets. The new film winds around the old one this way: Acacius is married to Lucilla (Connie Nielsen, in a welcome return), daughter of the now-deceased emperor Aurelius and the love of the late Maximus’s life. Enslaved and dragged to Rome to gladiate, the widower Lucius vows revenge on the general whose armies killed his wife. But there are things this angry young phenom must learn, about his ancestry and his destiny. It’s the movie’s worst-kept secret, but there’s a reason he keeps seeing footage of Russell Crowe from the first movie in his fever dreams. Battle follows battle, on the field, in the arena, in the nearest river, wherever, and usually with endless splurches of computer-generated blood. “Gladiator II” essentially bumper-cars its way through the mayhem, pausing for long periods of expository scheming about overthrowing the current regime. The prince of all fixers, a wily operative with interests in both managing gladiators and stocking munitions, goes by the name Macrinus. He’s played by Denzel Washington, who at one point makes a full meal out of pronouncing the word “politics” like it’s a poisoned fig. Also, if you want a masterclass in letting your robes do a lot of your acting for you, watch what Washington does here. He’s more fun than the movie but you can’t have everything. The movie tries everything, all right, and twice. Ridley Scott marshals the chaotic action sequences well enough, though he’s undercut by frenetic cutting rhythms, with that now-familiar, slightly sped-up visual acceleration in frequent use. (Claire Simpson and Sam Restivo are the editors.) Mescal acquits himself well in his first big-budget commercial walloper of an assignment, confined though he is to a narrower range of seething resentments than Crowe’s in the first film. I left thinking about two things: the word “politics” as savored/spit out by Washington, and the innate paradox of how Scott, whose best work over the decades has been wonderful, delivers spectacle. The director and his lavishly talented design team built all the rough-hewn sets with actual tangible materials the massive budget allowed. They took care to find the right locations in Morocco and Malta. Yet when combined in post-production with scads of medium-grade digital effects work in crowd scenes and the like, never mind the sharks, the movie’s a somewhat frustrating amalgam. With an uneven script on top of it, the visual texture of “Gladiator II” grows increasingly less enveloping and atmospherically persuasive, not more. But I hung there, for some of the acting, for some of the callbacks, and for the many individual moments, or single shots, that could only have come from Ridley Scott. And in the end, yes, you too may be moderately entertained. “Gladiator II” — 2.5 stars (out of 4) MPA rating: R (for strong bloody violence) Running time: 2:28 How to watch: Premieres in theaters Nov. 21. Michael Phillips is a Tribune critic.

WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, celebrated the closing of its business combination with Atlantic Coastal Acquisition Corp II (“ACAB”), a special purpose acquisition company, with a Nasdaq bell ringing ceremony. Abpro also celebrated the consummation of a PIPE offering raising $7 million in gross proceeds and a $2.76 million convertible note financing with YA II PN, LTD (“Yorkville”) to cover expenses in connection with the closing of the business combination. As previously announced, Abpro also has entered into a Standby Equity Purchase Agreement with Yorkville (the “SEPA”) pursuant to which Abpro has the right, but not the obligation, to issue up to $50 million in shares of its common stock to Yorkville upon registration of such shares, provided that no balance is outstanding on any promissory note to Yorkville (currently $3 million dollars outstanding). Among other restrictions and conditions set forth in the SEPA, the number of shares Abpro may request may not exceed the average of the daily traded amount of its shares of common stock during the five consecutive trading days preceding such request, and shall not cause Yorkville’s ownership to exceed 4.99% of the then outstanding common stock of Abpro, and the maximum amount of shares issued under the SEPA cannot exceed 19.99% of the outstanding common stock of Abpro without prior shareholder approval. Upon registration of the shares subject to the SEPA, Abpro has the right to receive financing for an additional $2 million. As previously announced, Abpro also has entered into a forward purchase agreement for the sale of up to 500,000 shares of common stock. Abpro believes that the various financings should significantly improve Abpro’s financial flexibility as it advances the development of its pipeline of its next-generation antibody therapies. “Becoming a public company represents a major milestone in our journey to provide solutions for patients with difficult-to-treat oncology and ophthalmology indications,” said Ian Chan, CEO and co-founder of Abpro. “The funds are expected to help accelerate the advancement of our pipeline to clinical trials. The financing will also provide the foundation for ongoing development of novel immunotherapies and next-generation antibody treatments in our pipeline with the aim of improving the lives of patients in need.” Abpro is advancing its pipeline of next-generation antibody therapies for HER2+ breast, gastric, and colorectal cancers, non-HER2+ gastric and liver cancer, wet age-related macular degeneration (AMD) and diabetic macular edema (DME), and infectious diseases. These next-generation antibodies are developed using Abpro's proprietary DiversImmune® platform, which creates antibody therapies against traditionally difficult targets. Abpro has partnered with Celltrion , a leading South Korean pharmaceutical company, in an exclusive global collaboration to further advance ABP 102, a T-cell engager, which is being developed for the treatment of HER2+ breast, gastric, and pancreatic cancers. Soo Young Lee, Senior Vice President and Head of the New Drug Division of Celltrion Inc. and a member of Abpro's Board of Directors, remarked, “Abpro’s ABP 102 drug candidate has shown preclinical data indicating the potential for better efficacy and less toxicity. We look forward to working closely with Abpro to advance ABP 102 into clinical trials.” Tony Eisenberg, who serves as a Director of Abpro, and had served as Chief Strategy Officer of ACAB prior to the business combination, added, “It’s an honor to be part of Abpro and the groundbreaking work they are doing. The Atlantic Coastal team is excited to have successfully completed this business combination with Abpro and to work with the Abpro management team to execute their long-term operational and strategic objectives as they develop next-generation antibody therapies with the potential to save lives and generate real return for investors.” Abpro’s Chairperson, Miles Suk, stated, "As the chairperson of the board, I am honored to guide Abpro through this landmark achievement. This listing marks a new chapter of growth and opportunity, and we remain committed to delivering sustainable value to our shareholders." About Abpro Abpro’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing a pipeline of next-generation antibody therapies, for HER2+ breast, gastric, and colorectal cancers, non-HER2+ gastric and liver cancer, wet age-related macular degeneration (AMD) and diabetic macular edema (DME), and infectious diseases. These antibodies are developed using Abpro's proprietary DiversImmune® platform. Abpro has partnered with Celltrion, which is a leading South Korean biotechnology company, ranked top 25 in the world by market capitalization, in an exclusive collaboration to further advance ABP 102, a T-cell engager, which is being developed for the treatment of HER2+ breast, gastric, and pancreatic cancer. Abpro is located in Woburn, Massachusetts. For more information, please visit www.abpro.com . Forward Looking Statements This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; Abpro’s ability to raise additional capital; the outcome of judicial proceedings to which Abpro or its subsidiaries is, or may become a party; failure to realize the anticipated benefits of the Business Combination, including difficulty in, or costs associated with, integrating the businesses of ACAB and Abpro; risks related to the rollout of Abpro’s business and the cost and timing of expected business milestones; the effects of competition on Abpro’s future business; and those factors discussed in Abpro’s public filings under the heading “Risk Factors,” and other documents of Abpro filed, or to be filed, with the SEC. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the “Risk Factors” section of Abpro’s public filings and other documents to be filed by Abpro from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward- looking statements, and while Abpro may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. Abpro does not give any assurance that Abpro will achieve its expectations. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. Contacts Company: info@abpro.com Investors: ir@abpro.com Media: Jessica Yingling, Ph.D., Little Dog Communications Inc. jessica@litldog.comChristmas came a little early for fans of indie and alternative artists with Nashville ties. After debuting a performance on The Tonight Show Starring Jimmy Fallon , Julien Baker and TORRES released their country single “Sugar in the Tank,” the first taste of a long-rumored collaboration album. The steady-rolling song is a change of pace for both artists, with pedal steel and banjo backing up simple, sweet lyrics promising serious devotion to a lover in the face of hesitation. The combination of TORRES’ low croon and Baker’s earnest high harmony communicate a desperation beyond words, as they sing: “I hate just watching through the window when you pull up / And I’m still thinking I should stay home / Come on baby, put a little sugar in the tank / And I love you all the way.” Though it’s the artists’ first foray into the genre’s twangiest regions, the song is a masterful ode to classic country love songs. And while TORRES (aka Mackenzie Scott) has written plenty of hopeful romantic tunes — see 2021’s Thirstier — this may be the first time Julien Baker has put out an upbeat song, at least without her boygenius bandmates. It’s nice to switch it up sometimes! Decked out with bolo ties and Nudie suits, the duo christened the tune with a live debut on Fallon on Tuesday and the track hit streaming services Friday. They’ve also announced a run of festival dates next year, including a stop at Knoxville’s Big Ears Festival in March. You can keep an eye for further dates and music announcements on their website , or by following Baker and TORRES on Instagram. LCD Soundsystem, Steve Lacy, boygenius and More Bring the Heat Julien Baker’s Little Oblivions Manifests a Change of Pace Year in Music 2018: Changing the Game Julien Baker Brings Hope to Marathon Music Works On Sprinter , Belmont alum Torres proves music still mattersTrump wants to turn the clock on daylight saving time

2024 is unquestionably the year of Balatro. It came out of nowhere to fill our heads with dreams of flush fives and legendary Jimbos. But I think what put it really over the top was when it launched on iOS and Android earlier this fall. That's because even though I don't have the numbers to prove it, Charlie Brooker — as he so often does in his show Black Mirror – made a particularly prescient prediction during an interview with Deadline when he said that after Balatro comes out on phones, "humankind's activity is going to drop about 25 percent." That said, I don't think people were prepared for the mobile version of Balatro to be an almost flawless example of how to properly translate a game from desktop to small screens and foldables. To start, on both the Apple App Store and Google Play, the mobile version of Balatro costs $10, which is actually $5 less than the desktop edition on Steam or the console ports on Switch, Xbox and PlayStation. But what's even better is that in a world where seemingly every phone game is crammed full of microtransactions, there are zero intrusive ads or other extra purchases to take away from the game. This includes all the crossover cardbacks (like the ones featuring characters from The Witcher, Cyberpunk 2077 and more) and the big forthcoming update due out at the beginning of next year. Photo by Sam Rutherford/Engadget On top of that, there's essentially no difference in features between the mobile and desktop/console versions. Granted, that's due in large part to the game... Sam Rutherford

Fatima Payman Apologies for Calling Pauline Hanson a Racist, “The Appropriate Term Is Fucking Racist”BOSTON , Dec. 13, 2024 /PRNewswire/ -- Below is the November 2024 Monthly Update for the Liberty All-Star Equity Fund USA . Liberty All-Star Equity Fund Ticker: USA Monthly Update, November 2024 Investment Approach: Fund Style: Large-Cap Core Fund Strategy: Combines three value-style and two growth-style investment managers. Those selected demonstrate a consistent investment philosophy, decision making process, continuity of key people and above-average long-term results compared to managers with similar styles. Investment Managers: Value Managers: Aristotle Capital Management, LLC Fiduciary Management, Inc. Pzena Investment Management, LLC Growth Managers: Sustainable Growth Advisers, LP TCW Investment Management Company Top 20 Holdings at Month-End: (34.5% of equity portfolio) 1 Microsoft Corp. 4.0 % 2 NVIDIA Corp. 3.7 % 3 Amazon.com, Inc. 2.7 % 4 Alphabet, Inc. 2.6 % 5 UnitedHealth Group, Inc. 2.3 % 6 Visa, Inc. 1.9 % 7 ServiceNow, Inc. 1.9 % 8 Meta Platforms, Inc. 1.7 % 9 Capital One Financial Corp. 1.5 % 10 S&P Global, Inc. 1.4 % 11 Charles Schwab Corp. 1.3 % 12 Fresenius Medical Care AG 1.2 % 13 Booking Holdings, Inc. 1.1 % 14 Sony Group Corp. 1.1 % 15 Ecolab, Inc. 1.1 % 16 Berkshire Hathaway, Inc. 1.0 % 17 Ferguson Enterprises, Inc. 1.0 % 18 Danaher Corp. 1.0 % 19 O'Reilly Automotive, Inc. 1.0 % 20 Wells Fargo & Co. 1.0 % Holdings are subject to change. Monthly Performance: Performance NAV Market Price Discount Beginning of month value $7.07 $7.03 -0.6 % Distributions (Ex-Date November 15 th ) $0.18 $0.18 End of month value $7.34 $7.30 -0.5 % Performance for month 6.38 % 6.40 % Performance year-to-date 20.39 % 26.68 % Net Assets at Month-End ($millions): Total $2,096.4 Equities $2,088.6 Percent Invested 99.6 % Sector Breakdown* (% of equity portfolio): Information Technology 22.5 % Financials 21.3 % Health Care 14.5 % Consumer Discretionary 12.5 % Industrials 9.2 % Communication Services 7.1 % Consumer Staples 4.6 % Materials 4.4 % Energy 1.8 % Utilities 1.5 % Real Estate 0.6 % Total Market Value 100.0 % *Based on Standard & Poor's and MSCI Global Industry Classification Standard (GICS). New Holdings None Holdings Liquidated: Arch Capital Group, Ltd. The net asset value (NAV) of a closed-end fund is the market value of the underlying investments (i.e., stocks and bonds) in the Fund's portfolio, minus liabilities, divided by the total number of Fund shares outstanding. However, the Fund also has a market price; the value at which it trades on an exchange. If the market price is above the NAV the Fund is trading at a premium. If the market price is below the NAV the Fund is trading at a discount. Performance returns for the Fund are total returns, which includes dividends, and are net of management fees and other Fund expenses. Returns are calculated assuming that a shareholder reinvested all distributions. Past performance cannot predict future investment results. Performance will fluctuate with changes in market conditions. Current performance may be lower or higher than the performance data shown. Performance information shown does not reflect the deduction of taxes that shareholders would pay on Fund distributions or the sale of Fund shares. Shareholders must be willing to tolerate significant fluctuations in the value of their investment. An investment in the Fund involves risk, including loss of principal. Sources of distributions to shareholders may include ordinary dividends, long-term capital gains and return of capital. The final determination of the source of all distributions in 2024 for tax reporting purposes will be made after year end. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund's investment experience during its fiscal year and may be subject to changes based on tax regulations. Based on current estimates a portion of the distributions consist of a return of capital. These estimates may not match the final tax characterization (for the full year's distributions) contained in shareholder 1099-DIV forms after the end of the year. All data is as of November 30, 2024 unless otherwise noted. Liberty All-Star® Equity Fund 1-800-241-1850 www.all-starfunds.com libinfo@alpsinc.com View original content to download multimedia: https://www.prnewswire.com/news-releases/liberty-all-star-equity-fund-november-2024-monthly-update-302331691.html SOURCE Liberty All-Star Equity Fund © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Ukraine must be in strong position for negotiations, Starmer to say

646 lodi 下载

Previous: 646-ph
Next: 646 jili

646 lodi

European Cup News

European Cup video analysis